Skip to main content

Table 3 Association of AGO2 haplotypes and breast cancer survival

From: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

  

Disease-free survival

    

Overall survival

 

Haplotype

Relapse, N (%)

No relapse, N (%)

aHR (95 % CI) a

P

Death, N (%)

Alive, N (%)

aHR (95 % CI) b

P

G-A-T-C-A

22 (25.9)

152 (39.9)

1 (reference)

 

9 (20.9)

167 (38.8)

1 (reference)

 

C-A-T-C-G

24 (28.2)

100 (26.3)

1.29 (0.71-2.34)

0.411

13 (30.2)

113 (26.2)

1.73 (0.72-4.13)

0.217

G-A-T-C-G

27 (31.8)

63(16.5)

2.66 (1.49-4.73)

0.001

15 (34.9)

78 (18.1)

3.11 (1.34-7.23)

0.008

G-A-C-C-A

5 (5.9)

12 (3.2)

1.76 (0.66-4.71)

0.262

2 (4.65)

16 (3.7)

2.22 (0.47-10.6)

0.316

Others

7 (8.24)

54 (14.2)

0.66 (0.28-1.56)

0.343

4 (9.3)

57 (13.2)

1.02 (0.31-3.33)

0.978

Total

85 (100)

381 (100)

  

43 (100)

431 (100)

  
  1. NOTE The AGO2 haplotype was composed of five SNPs in order of rs2292779, rs3864659, rs7016981, rs7824304, rs11786030.
  2. a Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no).
  3. b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node metastasis (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us